Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutationsKB407 transduction confirmed in all ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website ...

Sionna Therapeutics raised about $191 million in its initial public offering last February. Since then it's made progress with experimental treatments for cystic fibrosis. In June, the company ...

Krystal Biotech, Inc. KRYS expects preliminary unaudited net product revenues of $106-$107 million from lead drug Vyjuvek in ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

Residual CFTR function in cystic fibrosis was associated with better glucose tolerance and insulin secretion, with CFTR ...

As we age, we don't recover from injury or illness like we did when we were young. But new research from UCSF has found gene ...

The blood-brain and blood-retinal barriers are protective systems that prevent harmful substances from entering the brain and ...

Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...

Precision and timing of gene expression is essential for normal biological functions and, when disrupted, can lead to many ...